Skip to main content

Day: May 15, 2025

FitLife Brands Announces First Quarter 2025 Results

OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife” or the “Company”) (NASDAQ: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include:Total revenue was $15.9 million, 4% lower than the first quarter of 2024.   Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024. Gross margin was 43.1% compared to 44.0% during the first quarter of 2024. Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during the same period last year. Basic earnings per share and diluted earnings per share were $0.22 and $0.20, respectively, compared to $0.23 and...

Continue reading

Avicanna Reports Q1 2025 Results and First Profitable Quarter

TORONTO, May 15, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q1 2025 and the of the Company’s milestone of achieving its first profitable quarter. Management Commentary: “Starting 2025 with positive momentum, we are proud to report our first profitable quarter—a milestone that reflects our strategic focus and operational discipline. With this solid foundation, we are now positioned to focus on scaling our Canadian operations, international expansion, and advancing of our R&D pipeline and intellectual property” stated Aras Azadian, CEO of Avicanna. Q1 2025 Financial Highlights: First...

Continue reading

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations (microcystic LMs) has exceeded enrollment target of 40 patients; enrollment expected to close in June 2025 Phase 3 SELVA trial top-line results anticipated in the first quarter of 2026 Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for the treatment of cutaneous venous malformations top-line results on track for the fourth quarter of 2025 QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic LMs and cutaneous venous malformations Cash and cash equivalents of $75.6 million as of March 31, 2025, expected to fund operations into the second half of 2027 Company to host conference call at 8:30 a.m. ET today WAYNE,...

Continue reading

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Clinical data builds with CR in testicular cancer, enrollment in Phase 2 gastric trial, and new data in PD-1–resistant tumorsNear-term capital transactions poised to bolster liquidityNEW YORK, May 15, 2025 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the first quarter of 2025 and provided a business update highlighting continued clinical progress and strategic developments across its iNKT platform. The company will host a conference call and webcast today at 8:30 a.m. ET. “This quarter marks a turning point in the evolution of MiNK. Our platform is demonstrating the power of iNKT cells to transform immune responses in both...

Continue reading

Intchains Group Limited to Participate in the “Virtual Digital Assets Seminar” Presented by Benchmark Company on Tuesday, May 20th at 9:45 a.m. EDT

SINGAPORE, May 15, 2025 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies, and the active development of innovative Web3 applications, today announced it will be attending The Benchmark Company’s first iteration of their Virtual Digital Assets Seminar on Tuesday, May 20th EDT.  The event features virtual Fireside Chats with dynamic public and private Digital Assets companies, moderated by Mark Palmer, Benchmark’s Fintech & Digital Assets Senior Analyst. These interactive conversations offer a platform for companies to share their growth strategies, market insights, and leadership perspectives in a format that encourages thoughtful dialogue and deeper investor...

Continue reading

Cerro de Pasco Resources to Pursue Secondary Listing on the Lima Stock Exchange

MONTRÉAL, May 15, 2025 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV: CDPR) (OTCMKTS: GPPRF) (FRA: N8HP) (“CDPR” or the “Company”) is pleased to announce that it will pursue a secondary listing of its shares on the Lima Stock Exchange (Bolsa de Valores de Lima, “BVL”) as part of its strategy to expand its presence in Latin America and increase visibility among regional investors. The Company’s primary listing will remain on the TSX Venture Exchange (TSXV). The Company has retained Kallpa Securities SAB (“Kallpa”) as its sponsor and advisor for the listing process. Kallpa is a Peruvian investment firm specializing in equity sales, research, and corporate finance. It is the exclusive sponsor for all ten junior mining companies currently listed on the TSX Venture Exchange and cross-listed on the BVL. Since its founding in...

Continue reading

Ekso Bionics Accepted into NVIDIA Connect Program

Company unveils a strategic initiative to build the world’s first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics’ proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) — Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic initiative to build a proprietary foundation model for human motion, and to help develop and integrate related new artificial intelligence (“AI”)...

Continue reading

N2OFF Energy Targets European’s Energy Crises with Fourth Regional Battery Project

N2OFF to take part in financing a 35MW/140MWh planned Battery Energy Storage System project in Poland Neve Yarak, Israel, May 15, 2025 (GLOBE NEWSWIRE) — N2OFF, Inc.(NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in sustainable solutions for energy and innovation for agri- tech, recently announced its entry into the Polish renewable energy market by participating in the financing of a Battery Energy Storage System (BESS) project in Poland. The project, currently planned at 35MW/140MWh, represents a significant step in expanding Solterra’s large-scale energy storage solutions in the region. N2OFF, along with other lenders, will assist with financing an initial payment under a signed grid connection agreement. Future development plans include applying for an increase in capacity to more than 100MW/400MWh. According...

Continue reading

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, and CLIA laboratory to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the quarter ended March 31, 2025, and provided a corporate update. The Company reported a loss from continuing operations of approximately $2.3 million on total revenue of $110,310 for the quarter. Q1 2025 and Recent Highlights:Announced that, using publicly available datasets on drugs that have either been abandoned or discontinued by large pharmaceutical companies, Predictive has developed a registry of promising candidates that can potentially be repurposed...

Continue reading

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

Updated clinical data from Emi-Le Phase 1 dose escalation and backfill cohorts presented today at ESMO Breast Cancer 2025ORR increased to 31% across tumor types among evaluable patients with B7-H4 high tumors receiving intermediate doses Encouraging preliminary time-to-event data in triple-negative breast cancer (TNBC)Second, higher dose recently selected for expansion in post-topoisomerase-1 inhibitor ADC (post-topo-1) TNBC; patient enrollment advancing in both dose expansion cohorts Plan to report initial clinical data from expansion in second half of 2025 Conference call today at 8:00 a.m. ETCAMBRIDGE, Mass., May 15, 2025 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.